PL2392587T3 - Sekwencje i kompozycje peptydów - Google Patents

Sekwencje i kompozycje peptydów

Info

Publication number
PL2392587T3
PL2392587T3 PL11167363T PL11167363T PL2392587T3 PL 2392587 T3 PL2392587 T3 PL 2392587T3 PL 11167363 T PL11167363 T PL 11167363T PL 11167363 T PL11167363 T PL 11167363T PL 2392587 T3 PL2392587 T3 PL 2392587T3
Authority
PL
Poland
Prior art keywords
compositions
peptide sequences
peptide
sequences
Prior art date
Application number
PL11167363T
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparrós-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of PL2392587T3 publication Critical patent/PL2392587T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11167363T 2006-03-10 2007-03-09 Sekwencje i kompozycje peptydów PL2392587T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
EP07705325.4A EP2004676B1 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
EP11167363.8A EP2392587B1 (en) 2006-03-10 2007-03-09 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
PL2392587T3 true PL2392587T3 (pl) 2016-08-31

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11167363T PL2392587T3 (pl) 2006-03-10 2007-03-09 Sekwencje i kompozycje peptydów

Country Status (20)

Country Link
US (4) US20100055119A1 (pl)
EP (2) EP2392587B1 (pl)
JP (3) JP2009529570A (pl)
KR (1) KR20080106467A (pl)
CN (2) CN104558126B (pl)
AP (2) AP3642A (pl)
AU (1) AU2007226430B2 (pl)
BR (1) BRPI0708708A2 (pl)
CA (1) CA2645342A1 (pl)
DK (2) DK2392587T3 (pl)
EA (1) EA019733B1 (pl)
ES (2) ES2616341T3 (pl)
IL (2) IL193965A0 (pl)
MX (1) MX2008011520A (pl)
NO (1) NO20083576L (pl)
NZ (1) NZ570708A (pl)
PL (1) PL2392587T3 (pl)
SG (1) SG170092A1 (pl)
UA (1) UA97800C2 (pl)
WO (1) WO2007104932A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CA2932788A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
WO2004031211A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
US5776899A (en) 1993-10-14 1998-07-07 Seikagaku Corporation Polypeptide and anti-HIV agent prepared therefrom
US5756666A (en) 1993-10-19 1998-05-26 Ajinomoto Co., Inc. Peptides capable of inducing immune response to HIV
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
AU7689798A (en) * 1997-05-20 1998-12-11 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
PT2044950E (pt) 1997-09-18 2012-09-18 Univ Pennsylvania Cassetes de imunização adn de vif atenuadas para vacinas genéticas
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
JP2002540768A (ja) * 1999-02-19 2002-12-03 ユーリッヒ シューベルト ヒト免疫不全ウイルス１型（ＨＩＶ−１）ウイルス性調節タンパク質Ｒ（Ｖｐｒ）の合成ペプチドおよびその適用
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
EP1250351B1 (en) 2000-01-28 2005-11-30 Statens Serum Institut Methods to identify ctl epitopes of hiv
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
CN1549730A (zh) * 2000-10-04 2004-11-24 ���������Ǵ�ѧ�й��� 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
WO2002069691A2 (en) 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
AU2002331599A1 (en) * 2001-08-16 2003-03-03 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2004031345A2 (en) 2002-05-20 2004-04-15 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
CA2918585C (en) * 2003-09-17 2019-05-21 Duke University Consensus/ancestral immunogens
DK1778282T3 (en) * 2004-08-17 2016-06-06 Roussy Inst Gustave Mutated HIV NEF TO MODULATION OF IMMUNITY
WO2007024941A2 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine

Also Published As

Publication number Publication date
WO2007104932A2 (en) 2007-09-20
EA200870342A1 (ru) 2009-02-27
UA97800C2 (uk) 2012-03-26
JP6422698B2 (ja) 2018-11-14
AU2007226430A1 (en) 2007-09-20
US10034933B2 (en) 2018-07-31
CN104558126A (zh) 2015-04-29
EA019733B1 (ru) 2014-05-30
CN104558126B (zh) 2020-02-14
AP3642A (en) 2016-03-16
AP2015008680A0 (en) 2015-08-31
CN102443052A (zh) 2012-05-09
SG170092A1 (en) 2011-04-29
EP2004676B1 (en) 2016-11-16
JP2015007069A (ja) 2015-01-15
JP2009529570A (ja) 2009-08-20
US8992934B2 (en) 2015-03-31
BRPI0708708A2 (pt) 2011-06-07
KR20080106467A (ko) 2008-12-05
EP2392587A1 (en) 2011-12-07
HK1171027A1 (en) 2013-03-15
CA2645342A1 (en) 2007-09-20
US20150182618A1 (en) 2015-07-02
IL193965A0 (en) 2011-08-01
EP2392587B1 (en) 2016-05-04
IL219544A0 (en) 2012-06-28
US20130039937A1 (en) 2013-02-14
AU2007226430A2 (en) 2008-10-09
WO2007104932A3 (en) 2007-11-22
DK2392587T3 (en) 2016-05-23
US20170281750A1 (en) 2017-10-05
ES2616341T3 (es) 2017-06-12
CN102443052B (zh) 2014-12-31
AP2008004609A0 (en) 2008-10-31
DK2004676T3 (en) 2017-02-20
MX2008011520A (es) 2009-01-07
AU2007226430B2 (en) 2013-08-29
NO20083576L (no) 2008-12-10
ES2573105T3 (es) 2016-06-06
NZ570708A (en) 2011-12-22
JP2013040172A (ja) 2013-02-28
US20100055119A1 (en) 2010-03-04
US9675686B2 (en) 2017-06-13
EP2004676A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
IL251867B (en) Peptide sequences and compounds
GB0717864D0 (en) Peptide sequences and compositions
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
LT2178549T (lt) Antimikrobinis peptidas ir jo kompozicijos
EP2017283A4 (en) Peptides
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL195525A0 (en) Replikin peptides and uses thereof
GB0622399D0 (en) Novel compositions and uses thereof
GB0617171D0 (en) Novel compositions and methods
GB0604187D0 (en) Peptide and uses thereof
PL2392587T3 (pl) Sekwencje i kompozycje peptydów
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0618748D0 (en) Peptide
EP2091959A4 (en) IMPROVED PEPTIDE COMPOSITION
GB0622400D0 (en) Novel compositions and uses thereof
ZA200806753B (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions
GB0605774D0 (en) Peptide
IL192800A0 (en) Fgf2-binding peptides and uses thereof
HK1143743A (en) Peptide sequences and compositions
PL378824A1 (pl) Peptyd i jego zastosowanie
GB0612873D0 (en) Isolated peptides and uses thereof
GB0625230D0 (en) Compositions and methods